MAP2K7 and lung adenocarcinoma: However, Liu et al. reported a major pathologic response in a patient with stage IIIA p.(V600E) lung adenocarcinoma who underwent a neoadjuvant-targeted therapy with BRAF and MEK inhibitors followed by radical surgical excision [45].